Literature DB >> 3001234

Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicin, and asparaginase consolidation for acute nonlymphocytic leukemia.

B L Powell, R L Capizzi, E S Lyerly, M R Cooper.   

Abstract

Two patients with acute nonlymphocytic leukemia (ANLL) developed peripheral motor and sensory neuropathies after consolidation chemotherapy with high-dose cytosine arabinoside (ara-C), daunorubicin, and asparaginase. Evidence for ara-C and daunorubicin-induced peripheral neuropathies is reported. Despite the frequent use of these agents, only two cases of peripheral neuropathy after systemic therapy have been previously described; neurotoxic effects may be potentiated and become clinically important when the three drugs are used in combination.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3001234     DOI: 10.1200/JCO.1986.4.1.95

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

1.  Polyneuritis after HD Ara-C therapy for malignant lymphoma.

Authors:  L Montalbetti; G Brambilla Pisoni; G Trotti; M V Calloni
Journal:  Ital J Neurol Sci       Date:  1992-02

Review 2.  High-dose cytosine arabinoside: pharmacological and clinical aspects.

Authors:  W G Peters; L P Colly; R Willemze
Journal:  Blut       Date:  1988-01

Review 3.  The toxicity of cytarabine.

Authors:  J Stentoft
Journal:  Drug Saf       Date:  1990 Jan-Feb       Impact factor: 5.606

Review 4.  Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management.

Authors:  Carla C P Verstappen; Jan J Heimans; Klaas Hoekman; Tjeerd J Postma
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  Cytosine arabinoside affects the heat and capsaicin receptor TRPV1 localisation and sensitivity in human sensory neurons.

Authors:  Uma Anand; William R Otto; Chas Bountra; Iain Chessell; Marco Sinisi; Rolfe Birch; Praveen Anand
Journal:  J Neurooncol       Date:  2008-04-15       Impact factor: 4.130

6.  Cisplatin, ara-C and etoposide (PAE) in the treatment of recurrent childhood brain tumors.

Authors:  B J Corden; L C Strauss; T Killmond; B S Carson; M D Wharam; A J Kumar; S Piantadosi; P A Robb; P C Phillips
Journal:  J Neurooncol       Date:  1991-08       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.